Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China

被引：0
|
作者：
Haijing Guan
Chunping Wang
Zhigang Zhao
Sheng Han
机构：
[1] Capital Medical University,Department of Pharmacy, Beijing Tiantan Hospital
[2] Peking University,China Center for Health Economic Research
[3] Peking University,International Research Center for Medicinal Administration
[4] Peking University,School of Pharmaceutical Sciences
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
Donafenib; Cost-effectiveness; Partitioned survival model; Unresectable hepatocellular carcinoma; China;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3334 / 3346
页数：12
相关论文
共 50 条
  • [1] Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
    Guan, Haijing
    Wang, Chunping
    Zhao, Zhigang
    Han, Sheng
    ADVANCES IN THERAPY, 2022, 39 (07) : 3334 - 3346
  • [2] Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Meng, Rui
    Zhang, Xueke
    Zhou, Ting
    Luo, Mengjie
    Qiu, Yijin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (07) : 1079 - 1086
  • [3] The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
    Meng, Rui
    Cao, Yingdan
    Zhou, Ting
    Hu, Hongfei
    Qiu, Yijin
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [4] First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Wang, Liting
    Peng, Ye
    Qin, Shuxia
    Wan, Xiaomin
    Zeng, Xiaohui
    Li, Sini
    Liu, Qiao
    Tan, Chongqing
    PLOS ONE, 2023, 18 (04):
  • [5] Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
    Chen, Qiuping
    Sun, Quan
    Zhang, Jing
    Li, Baixue
    Feng, Quansheng
    Liu, Jibin
    PLOS ONE, 2024, 19 (03):
  • [6] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [7] Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma
    Zou, Huimin
    Lai, Yunfeng
    Chen, Xianwen
    Ung, Carolina Oi Lam
    Hu, Hao
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
  • [8] ASSESSING THE COST-EFFECTIVENESS OF LENVATINIB AS A FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CANADA
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    MEDICAL DECISION MAKING, 2020, 40 (01) : E3 - E4
  • [9] Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
    Zhang, Pengfei
    Yang, Yu
    Wen, Feng
    He, Xiaofeng
    Tang, Ruilei
    Du, Zedong
    Zhou, Jing
    Zhang, Jian
    Li, Qiu
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (07) : 853 - 859
  • [10] COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Li, X.
    Wudong, G.
    Wang, Y.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
12345